

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding the Phase III RELEVANCE study comparing rituximab with chemotherapy (R-chemo) to lenalidomide/rituximab (R<sup>2</sup>), each followed by maintenance rituximab, for previously untreated follicular lymphoma (FL)?**
  - a. Progression-free survival was significantly improved with R<sup>2</sup>
  - b. The rate of complete remission was significantly improved with R<sup>2</sup>
  - c. R<sup>2</sup> and R-chemo demonstrated similar efficacy**
- 2. Which of the following drug types best describes the mechanism of action of the recently FDA-approved agent tazemetostat?**
  - a. PI3 kinase inhibitor
  - b. Immune checkpoint inhibitor
  - c. EZH2 inhibitor**
- 3. The results of the National LymphoCare Study demonstrated which of the following 5-year overall survival outcomes for patients with FL who received first-line R-CHOP and experienced early disease progression (within 2 years of diagnosis) compared to those who received first-line R-CHOP and did not experience early relapse?**
  - a. Inferior survival outcomes**
  - b. Similar survival outcomes
- 4. Which of the following statements is true regarding idelalisib in the treatment of FL?**
  - a. It inhibits both PI3K alpha and PI3K delta and is administered intravenously
  - b. It inhibits PI3K delta only and is administered orally**
- 5. Which of the following drug types best describes the mechanism of action of the novel agent mosunetuzumab?**
  - a. T-cell engaging bispecific antibody**
  - b. CAR (chimeric antigen receptor) T-cell therapy
  - c. Antibody-drug conjugate